Cite
HARVARD Citation
Kutsch, N. et al. (2022). Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere. 6 (4), pp. e692-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kutsch, N. et al. (2022). Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere. 6 (4), pp. e692-. [Online].